User profiles for David Gandara
 | David GandaraProfessor of Medicine Verified email at ucdavis.edu Cited by 49564 |
[HTML][HTML] Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer
Background We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs
overall survival among patients with completely resected early-stage non–small-cell lung …
overall survival among patients with completely resected early-stage non–small-cell lung …
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1)
monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 …
monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 …
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Background Results from phase II studies in patients with stage IIIA non-small-cell lung cancer
with ipsilateral mediastinal nodal metastases (N2) have shown the feasibility of resection …
with ipsilateral mediastinal nodal metastases (N2) have shown the feasibility of resection …
[PDF][PDF] Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung …
…, L Simms, KP Sugarman, D Gandara - Journal of clinical …, 2008 - journals.viamedica.pl
Cel. Cisplatyna z gemcytabiną jest standardowym leczeniem I linii chorych na zaawansowanego
niedrobnokomórkowego raka płuca (NSCLC). Badania kliniczne II fazy wykazały …
niedrobnokomórkowego raka płuca (NSCLC). Badania kliniczne II fazy wykazały …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
…, GA Otterson, LT Campos, DR Gandara… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a …
…, VK Israel, RB Livingston, DR Gandara - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: This randomized trial was designed to determine whether paclitaxel plus carboplatin
(PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for patients with …
(PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for patients with …
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
DR Gandara, SM Paul, M Kowanetz, E Schleifman… - Nature medicine, 2018 - nature.com
Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are
broadly efficacious, improved outcomes have been observed in patients with high PD-L1 …
broadly efficacious, improved outcomes have been observed in patients with high PD-L1 …
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum …
…, V Miller, JS Lee, M Moore, D Gandara… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase
III trial was conducted of chemotherapy for patients with advanced non–small-cell lung …
III trial was conducted of chemotherapy for patients with advanced non–small-cell lung …
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest …
…, CA Presant, RJ McKenna, DR Gandara - Journal of Clinical …, 1995 - ascopubs.org
PURPOSE To assess the feasibility of concurrent chemotherapy and irradiation (chemoRT)
followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) in a …
followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) in a …
Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer
RVN Lord, J Brabender, D Gandara, V Alberola… - Clinical Cancer …, 2002 - AACR
Purpose: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which
is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence …
is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence …